Clinical Trials on Haemophilia A With Inhibitors

Total 1025 results

Baxalta now part of Shire

Completed

BAX 855 Pediatric Study

Hemophilia A

United States, Spain, United Kingdom, Taiwan, Malaysia, Bulgaria, Hong Kong, Korea, Republic of, Netherlands, Turkey, Ukraine
Baxalta now part of Shire
Baxalta Innovations GmbH, now part of Shire

Completed

Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery

Hemophilia A

United States, Belgium, France, Norway, Netherlands, Austria, Hungary, Italy, Poland, Portugal, Romania, Russian Federation, Spain, Sweden
Baxalta now part of Shire

Terminated

First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients

Hemophilia

United Kingdom
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A

Hemophilia A

United States, Canada, Puerto Rico
Lund University

Completed

Optimizing the Use of Prophylaxis in Patients With Severe Haemophilia A (myPKFiT)

Hemophilia A

Sweden
Baxalta now part of Shire

Completed

GAS-Hem Feasibility Study

Hemophilia A

Canada, United States
Delta University for Science and Technology

Unknown

Pulsed Electromagentic Field in Haemophilia

Hemophilia A

Egypt
Victor Blanchette
Queen's University; Sydney Children's Hospitals Network; Royal Children's Hospital and other collaborators

Unknown

Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia

Hemophilia A
Kaifeng Pharmaceutical (Group) Co., Ltd.
Beijing Furen Biomedical Research Institute Co., Ltd.

Unknown

A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Hemophilia A

China
Nationwide Children's Hospital
The Hospital for Sick Children

Completed

Exercise Versus DDAVP in Patients With Mild Hemophilia A

Hemophilia A

United States
Octapharma

Completed

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A

Hemophilia A

United States, Germany, Bulgaria
Bayer

Completed

BAY94-9027 PK Study Comparing to Another Long Acting Product

Hemophilia A

Bulgaria
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

Hemophilia A

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.

Hemophilia A

China
FH Campus Wien, University of Applied Sciences
Medical University of Vienna; Shire

Completed

Gait Examination in Patients With Hemophilia in Austria (JOSEPHA)

Hemophilia

Austria
Pfizer

Completed

Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting

Hemophilia A

Spain, France, Turkey, Netherlands, Germany, Italy, Ukraine
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral FVIII Gene Therapy

Hemophilia A

China
Pfizer

Completed

Study Evaluating Pharmacovigilance Of Refacto AF

Hemophilia A

Germany, Austria
University Hospital, Brest

Completed

Health Practice of Hemophilia Patiente Care During Pregnancy, Delivery and Newborn Children (ECHANGE)

Hemophilia

France
Fondazione Angelo Bianchi Bonomi
Sintesi Research Srl

Completed

Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET)

Hemophilia A

United States, India, Spain, Argentina, Austria, Brazil, Chile, Egypt, Iran, Islamic Republic of, Italy, Mexico, Saudi Arabia, South Africa, Turkey
CSL Behring
Parexel

Completed

Study of Biostate® in Children With Hemophilia A

Hemophilia A

Ukraine, Lebanon, Belarus, Georgia, Guatemala, Mexico
Pfizer

Completed

PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A

Hemophilia A

China
University Hospital, Toulouse

Completed

Could Physical Activity Help to Counteract the Blood Haemophilia Disturbance? A Pilot Study. (END-HEMO)

Hemophilia A

France
Pfizer

Completed

Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients

Hemophilia A

Spain, Finland, Serbia, Georgia, Italy, Romania, Sweden, Turkey, Ukraine
Children's Hospital Los Angeles
University of Vermont

Completed

Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay

Hemophilia A

United States
University Hospital, Caen

Completed

Evaluation of Clot Stability Induced by Solulin: Evaluation of New Solulin Mutants Lacking Protein C Activation Capacity (SOLUCLOT)

Hemophilia A

France
Taiwan Society of Thrombosis and Hemostasis
China Medical University Hospital; Kaohsiung Medical University Chung-Ho Memorial... and other collaborators

Unknown

Outcomes of Prophylaxis and On-demand Treatment for Severe Hemophiliacs and Collection of Baseline Data in Hemophiliacs in Taiwan

Hemophilia
Pfizer

Completed

Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A

Hemophilia A

China
The University of Texas Health Science Center,...

Completed

Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia

Hemophilia A

United States
Bayer

Completed

Colorado Adult Joint Assessment Scale (CAJAS) Validation (CAJAS)

Hemophilia A

United States
Bayer

Completed

Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery (NO PEACKS)

Hemophilia A

Germany, Spain, Austria, Italy, Slovenia, Greece, Netherlands
Tri-Service General Hospital

Unknown

The Effect of Functional Activities and Balance Ability With Taping in Subjects of Hemophilia

Hemophilia
Bayer

Terminated

Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A

Hemophilia A

United States
Bayer

Completed

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

Hemophilia A

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Unknown

Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A

Hemophilia A
Pfizer

Terminated

Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings

Hemophilia A

Netherlands, Spain, Greece, Italy, France, Belgium, Germany, Austria, Sweden, Hungary, Finland, United Kingdom, Denmark, Romania
Bayer

Completed

Kogenate FS Regulatory Post-Marketing Surveillance (KG0910KR)

Hemophilia A

Korea, Republic of
Green Cross Corporation
Atlantic Research Group

Unknown

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

Hemophilia A

United States, Canada, New Zealand, Poland, Russian Federation, Ukraine, United Kingdom
Bayer

Terminated

BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A

Hemophilia A

Belgium, Italy, Spain, United States, Canada, Switzerland, Estonia, Taiwan, France, Chile, Netherlands, United Kingdom, Austria, New Zealand, South Africa, Romania, Croatia, Israel, Germany, Poland, Australia, Denmark, Turkey, Argentina, Lithuan... and more
Pfizer

Completed

Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)

Hemophilia A

United Kingdom, Hungary, Bulgaria
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Study Evaluating Inhibitor Specificity in Hemophilia A

Hemophilia A

Belgium, Italy, Spain, United States, United Kingdom, Germany, France
Green Cross Corporation

Completed

Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A

Hemophilia A
CSL Behring
Parexel

Completed

Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A

Hemophilia A

Bulgaria, Poland, Russian Federation, Macedonia, The Former Yugoslav Republic of
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Refacto For Pharmacovigilance

Hemophilia A

Germany, Austria
Bayer

Completed

BAY14-2222 Continuous Infusion in Surgeries

Hemophilia

Israel
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

Hemophilia A

Poland, Belgium, France, Italy, Spain, United States, Australia, Netherlands, New Zealand, Sweden, Germany, Finland, Hungary
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery

Hemophilia A

United States
Christian Medical College, Vellore, India

Unknown

Musculoskeletal Function in Hemophilia

Hemophilia

India, Argentina, Brazil, Egypt, Iran, Islamic Republic of, Singapore, South Africa, Thailand, Venezuela
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A

Hemophilia A

China
Staidson (Beijing) Biopharmaceuticals Co., Ltd

Recruiting

Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor

Hemophilia

China

Clinical Trials on Haemophilia A With Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations